(NYSEMKT: AIM) Aim Immunotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.95%.
Aim Immunotech's earnings in 2026 is -$14,129,000.On average, 3 Wall Street analysts forecast AIM's earnings for 2026 to be -$34,674,376, with the lowest AIM earnings forecast at -$36,774,160, and the highest AIM earnings forecast at -$32,694,352. On average, 3 Wall Street analysts forecast AIM's earnings for 2027 to be -$47,576,470, with the lowest AIM earnings forecast at -$57,508,527, and the highest AIM earnings forecast at -$37,305,094.
In 2027, AIM is forecast to generate -$21,772,283 in earnings, with the lowest earnings forecast at -$27,776,227 and the highest earnings forecast at -$15,508,859.